- Home
- ESGL vs MGNX Comparison
ESGL vs MGNX Comparison
Compare ESGL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- MGNX
- Stock Information
- Founded
- ESGL 1999
- MGNX 2000
- Country
- ESGL Singapore
- MGNX United States
- Employees
- ESGL N/A
- MGNX N/A
- Industry
- ESGL
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ESGL
- MGNX Health Care
- Exchange
- ESGL Nasdaq
- MGNX Nasdaq
- Market Cap
- ESGL 99.1M
- MGNX 97.2M
- IPO Year
- ESGL N/A
- MGNX 2013
- Fundamental
- Price
- ESGL $2.41
- MGNX $1.36
- Analyst Decision
- ESGL
- MGNX Hold
- Analyst Count
- ESGL 0
- MGNX 9
- Target Price
- ESGL N/A
- MGNX $5.33
- AVG Volume (30 Days)
- ESGL 44.2K
- MGNX 378.7K
- Earning Date
- ESGL 06-10-2025
- MGNX 05-13-2025
- Dividend Yield
- ESGL N/A
- MGNX N/A
- EPS Growth
- ESGL N/A
- MGNX N/A
- EPS
- ESGL N/A
- MGNX N/A
- Revenue
- ESGL $6,099,784.00
- MGNX $154,050,000.00
- Revenue This Year
- ESGL N/A
- MGNX N/A
- Revenue Next Year
- ESGL N/A
- MGNX $45.52
- P/E Ratio
- ESGL N/A
- MGNX N/A
- Revenue Growth
- ESGL N/A
- MGNX 255.31
- 52 Week Low
- ESGL $0.90
- MGNX $0.99
- 52 Week High
- ESGL $3.00
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- ESGL 64.57
- MGNX 39.88
- Support Level
- ESGL $2.06
- MGNX $1.44
- Resistance Level
- ESGL $2.44
- MGNX $1.58
- Average True Range (ATR)
- ESGL 0.18
- MGNX 0.11
- MACD
- ESGL 0.03
- MGNX -0.02
- Stochastic Oscillator
- ESGL 95.89
- MGNX 17.65
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.